vs

Side-by-side financial comparison of Galecto, Inc. (GLTO) and REZOLVE AI PLC (RZLV). Click either name above to swap in a different company.

REZOLVE AI PLC is the larger business by last-quarter revenue ($1.2M vs $1.0M, roughly 1.2× Galecto, Inc.). REZOLVE AI PLC runs the higher net margin — -1078.8% vs -20053.5%, a 18974.8% gap on every dollar of revenue.

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.

REZOLVE AI PLC is a UK-based technology firm developing AI-powered mobile engagement and instant transaction platforms. Its solutions let consumers complete purchases directly from audio, video, and print content, serving retail, consumer goods, and media clients across Europe, North America, and select APAC markets.

GLTO vs RZLV — Head-to-Head

Bigger by revenue
RZLV
RZLV
1.2× larger
RZLV
$1.2M
$1.0M
GLTO
Higher net margin
RZLV
RZLV
18974.8% more per $
RZLV
-1078.8%
-20053.5%
GLTO

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
GLTO
GLTO
RZLV
RZLV
Revenue
$1.0M
$1.2M
Net Profit
$-200.7M
$-13.0M
Gross Margin
Operating Margin
-20149.5%
-808.4%
Net Margin
-20053.5%
-1078.8%
Revenue YoY
339.0%
Net Profit YoY
-2877.8%
EPS (diluted)
$10.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GLTO
GLTO
RZLV
RZLV
Q4 25
$1.0M
Q2 25
$1.2M
Q4 24
$228.0K
Q3 24
$146.0K
Q2 24
$213.0K
Q1 24
$257.0K
Q4 23
$340.0K
Q3 23
$473.0K
Net Profit
GLTO
GLTO
RZLV
RZLV
Q4 25
$-200.7M
Q2 25
$-13.0M
Q4 24
$-6.7M
Q3 24
$-3.9M
Q2 24
$-5.3M
Q1 24
$-5.5M
Q4 23
$-6.5M
Q3 23
$-8.1M
Operating Margin
GLTO
GLTO
RZLV
RZLV
Q4 25
-20149.5%
Q2 25
-808.4%
Q4 24
-3114.9%
Q3 24
-2630.1%
Q2 24
-2618.3%
Q1 24
-2233.9%
Q4 23
-1962.1%
Q3 23
-1814.6%
Net Margin
GLTO
GLTO
RZLV
RZLV
Q4 25
-20053.5%
Q2 25
-1078.8%
Q4 24
-2956.6%
Q3 24
-2659.6%
Q2 24
-2506.1%
Q1 24
-2131.1%
Q4 23
-1904.4%
Q3 23
-1720.1%
EPS (diluted)
GLTO
GLTO
RZLV
RZLV
Q4 25
$10.86
Q2 25
Q4 24
$-5.17
Q3 24
$-3.39
Q2 24
$-4.92
Q1 24
$-5.05
Q4 23
$-27.66
Q3 23
$-7.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GLTO
GLTO
RZLV
RZLV
Cash + ST InvestmentsLiquidity on hand
$257.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$240.4M
$-14.3M
Total Assets
$260.5M
$80.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GLTO
GLTO
RZLV
RZLV
Q4 25
$257.6M
Q2 25
Q4 24
$14.2M
Q3 24
$19.7M
Q2 24
Q1 24
$27.2M
Q4 23
$33.2M
Q3 23
$44.2M
Stockholders' Equity
GLTO
GLTO
RZLV
RZLV
Q4 25
$240.4M
Q2 25
$-14.3M
Q4 24
$15.8M
Q3 24
$20.9M
Q2 24
$23.6M
Q1 24
$28.2M
Q4 23
$32.3M
Q3 23
$37.4M
Total Assets
GLTO
GLTO
RZLV
RZLV
Q4 25
$260.5M
Q2 25
$80.1M
Q4 24
$17.1M
Q3 24
$23.4M
Q2 24
Q1 24
$32.5M
Q4 23
$38.2M
Q3 23
$50.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GLTO
GLTO
RZLV
RZLV
Operating Cash FlowLast quarter
$566.0K
$-4.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GLTO
GLTO
RZLV
RZLV
Q4 25
$566.0K
Q2 25
$-4.9M
Q4 24
$-4.9M
Q3 24
$-3.7M
Q2 24
$-4.1M
Q1 24
$-5.9M
Q4 23
$-11.5M
Q3 23
$-8.5M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons